Search - Archive ouverte HAL Access content directly

Filter your results

11 Results
Structure: Internal structure identifier : 300097

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

A. Hospital , T. Prebet , S. Bertoli , X. Thomas , E. Tavernier et al.
Blood, 2014, 124 (8), pp.1312 - 1319. ⟨10.1182/blood-2014-01-549212⟩
Journal articles hal-01688071v1

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

Hervé Avet-Loiseau , Cyrille Hulin , Loic Campion , Philippe Rodon , Gerald Marit et al.
Journal of Clinical Oncology, 2013, 31 (22), pp.2806--2809. ⟨10.1200/JCO.2012.46.2598⟩
Journal articles hal-01064339v1

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.

Jean-Luc Harousseau , Herve Avet-Loiseau , Michel Attal , Catherine Charbonnel , Frederic Garban et al.
Journal of Clinical Oncology, 2009, 27 (34), pp.5720-6. ⟨10.1200/JCO.2008.21.1060⟩
Journal articles hal-00821143v1
Image document

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

Nicolas Boissel , Aline Renneville , Thibaut Leguay , Pascale Cornillet Lefebvre , Christian Recher et al.
Haematologica, 2015, 100 (6), pp.780 - 785. ⟨10.3324/haematol.2014.114884⟩
Journal articles inserm-01820455v1
Image document

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Vincent Ribrag , Serge Koscielny , Jacques Bosq , Thibaut Leguay , Olivier Casasnovas et al.
The Lancet, 2016, 387 (10036), pp.2402 - 2411. ⟨10.1016/S0140-6736(15)01317-3⟩
Journal articles inserm-01419476v1
Image document

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis

Charles Herbaux , Nicolas Duployez , Catherine Badens , Nicolas Poret , Claude Gardin et al.
American Journal of Hematology, 2015, 90 (8), pp.737-738. ⟨10.1002/ajh.24073⟩
Journal articles inserm-02913994v1
Image document

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A Ascierto , Michele Del Vecchio , Caroline Robert , Andrzej Mackiewicz , Vanna Chiarion-Sileni et al.
Lancet Oncology, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Journal articles inserm-01807340v1
Image document

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Emmanuel Bachy , Roch Houot , Franck Morschhauser , Anne Sonet , Pauline Brice et al.
Haematologica, 2013, 98 (7), pp.1107-14. ⟨10.3324/haematol.2012.082412⟩
Journal articles hal-00933219v1
Image document

Bortezomib-doxorubicin-cyclophosphamide-dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the IFM

Bruno Royer , Minvielle Stéphane , Momar Diouf , Murielle Roussel , Lionel Karlin et al.
Journal of Clinical Oncology, 2016, 34 (18), pp.2125-2132. ⟨10.1200/JCO.2015.63.1929⟩
Journal articles inserm-01273359v1

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Xavier Leleu , Michel Attal , Bertrand Arnulf , Philippe Moreau , Catherine Traulle et al.
Blood, 2013, 121 (11), pp.1968--1975. ⟨10.1182/blood-2012-09-452375⟩
Journal articles hal-01064417v1

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Michel Attal , Valerie Lauwers-Cances , Gerald Marit , Denis Caillot , Philippe Moreau et al.
New England Journal of Medicine, 2012, 366 (19), pp.1782-91. ⟨10.1056/NEJMoa1114138⟩
Journal articles hal-00852275v1